Mass Spec Data Digital Transformation at Lilly Biologics Discovery
Learn from Dr. Joomi Ahn how Lilly’s Biologics Discovery Mass Spectrometry group implemented Genedata Expressionist to transform unstructured mass spectrometry (MS) data into a structured, automated digital ecosystem. Integration with electronic lab notebook, liquid handling automation, and custom AI/ML tools enabled 3-10x productivity gains.
High-throughput workflows now process a large number of samples per batch for intact mass, bispecific assembly checks, and stability peptide mapping workflows. Vendor-neutral architecture supports cross-site standardization while enabling sequence liability prediction models and automated stability reporting, accelerating biologics drug discovery.
You will learn how to:
- Standardize MS workflows across sites with a scalable, vendor-neutral, flexible platform.
- Automate end-to-end MS processes to increase productivity, data integrity, and knowledge access.
- Integrate wet and digital labs to shorten developability timelines for any new and hybrid modality.
- Leverage sequence liability prediction and automated stability reporting to accelerate drug candidate selection.
Who Should Watch
- Analytical scientists and innovation leaders looking for scalable, vendor-neutral ways to standardize and automate MS workflows across labs and sites.
- Developability and CMC characterization stakeholders using MS data and digital platforms to streamline biologics discovery and development, reduce optimization cycles, and accelerate timelines.
- VP/Director-level biopharma leaders building digital foundations in R&D and evaluating how AI and digital tools can accelerate timelines and deliver measurable impact.
- IT, informatics, and scientific software developers integrating legacy systems, enabling scalable infrastructure, and delivering user-friendly tools that strengthen scientific workflows.
